ARS Pharmaceuticals (SPRY) said Monday it has granted ALK-Abello exclusive rights to commercialize neffy nasal spray, its emergency treatment for Type I allergic reactions, in Europe, Canada, and other territories outside the US.
Under the licensing agreement, ARS Pharmaceuticals said it will receive $145 million upfront and up to $320 million in milestone payments, along with royalties.
ARS will manufacture and supply neffy to ALK-Abello and retain US rights while there are no changes to partnerships for neffy in Japan, China, Australia and New Zealand, ARS Pharmaceuticals added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments